公开(公告)号：US09480751B2

公开(公告)日：2016-11-01

申请号：US14111347

申请日：2012-04-04

Applicant: Yoram Shechter ,  Matityahu Fridkin

Inventor： Yoram Shechter ,  Matityahu Fridkin

IPC: A61K38/00 ,  A61K47/48 ,  C07C309/17 ,  C07D207/46 ,  C07D213/70 ,  A61K38/22 ,  A61K38/28 ,  A61K38/37 ,  A61K38/48

CPC classification number: A61K47/48038 ,  A61K38/22 ,  A61K38/28 ,  A61K38/37 ,  A61K38/4846 ,  A61K47/542 ,  C07C309/17 ,  C07D207/46 ,  C07D213/70 ,  C12Y304/21021

Abstract: The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof.

Abstract translation: 本发明提供了一种长链脂肪酸（LCFA）样白蛋白结合探针/配体，其不含可水解键并且与人血清白蛋白具有增强的缔合亲和力，其在与含氨基或巯基的短寿命药物 和施用所述缀合物，显着延长所述药物的使用寿命，而基本上不干扰其药理学活性。 本发明还提供了所述探针与含氨基或巯基的药物的结合物，以及药物组合物及其用途。

公开(公告)号：US20160294224A1

公开(公告)日：2016-10-06

申请号：US15177418

申请日：2016-06-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yaron SILBERBERG ,  Haim SUCHOWSKI ,  Nikolay V. VITANOV ,  Andon A. RANGELOV

IPC: H02J50/12 ,  H01F38/14

CPC classification number: H02J50/12 ,  H01F38/14 ,  H02J5/005

Abstract: A method or apparatus for wireless transferring energy between a source coil and a drain coil, comprises setting an initial resonant frequency of the source coil as a first condition; setting the source coil and said drain coil in positions relative to each other to define an initial coupling coefficient therebetween, so that the initial coupling coefficient comprises a second condition; and adiabatically changing one or both of the conditions while pumping energy into the source coil. The source coil energy is transferred to the drain coil over the course of the adiabatic change.

Abstract translation: 一种用于在源极线圈和漏极线圈之间无线传输能量的方法或装置，包括将源极线圈的初始谐振频率设置为第一条件; 将源极线圈和所述漏极线圈设置在相对于彼此的位置以限定其间的初始耦合系数，使得初始耦合系数包括第二条件; 并绝热地改变一个或两个条件，同时将能量泵入源线圈。 在绝热变化的过程中，源极线圈能量被传递到漏极线圈。

公开(公告)号：US20160279169A1

公开(公告)日：2016-09-29

申请号：US15180152

申请日：2016-06-13

Applicant: Ramot at Tel-Aviv University Ltd. ,  Yeda Research and Development Co. Ltd.

Inventor： Daniel OFFEN ,  Michal DADON-NACHUM ,  Tali BEN-ZUR ,  Eldad MELAMED ,  David YAFFE

IPC: A61K35/34 ,  A61K38/30 ,  C12N5/077 ,  A61K38/18

CPC classification number: A61K35/34 ,  A61K35/12 ,  A61K38/00 ,  A61K38/185 ,  A61K38/1866 ,  A61K38/30 ,  C12N5/0658 ,  C12N5/0659 ,  C12N2501/105 ,  C12N2501/13 ,  C12N2501/165 ,  C12N2510/00

Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.

公开(公告)号：US09410131B2

公开(公告)日：2016-08-09

申请号：US13576720

申请日：2011-02-10

Applicant: Ron Milo ,  Arren Bar-Even ,  Elad Noor

Inventor： Ron Milo ,  Arren Bar-Even ,  Elad Noor

IPC: C12N9/04 ,  C12N15/82 ,  C12N9/02 ,  C12N9/12 ,  C12N9/10 ,  C12N9/18 ,  C12N9/88 ,  C12N9/90 ,  C12N9/00 ,  C12P7/40 ,  G06F19/12

CPC classification number: C12N9/93 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/1018 ,  C12N9/1205 ,  C12N9/13 ,  C12N9/18 ,  C12N9/88 ,  C12N9/90 ,  C12N15/70 ,  C12N15/8245 ,  C12N15/8247 ,  C12N15/8269 ,  C12P7/40 ,  C12P7/42 ,  C12P7/46 ,  C12P11/00 ,  C12Y101/01059 ,  C12Y102/01018 ,  C12Y201/03001 ,  C12Y208/03001 ,  C12Y401/01031 ,  C12Y402/01017 ,  C12Y402/01054 ,  C12Y604/01001 ,  C12Y604/01002 ,  G06F19/12 ,  Y02P20/52

Abstract: A system for carbon fixation is provided. The system comprises enzymes which catalyze reactions of a carbon fixation pathway, wherein at least one of the reactions of the carbon fixation pathway is a carboxylation reaction, wherein products of the reactions of the carbon fixation pathway comprise oxaloacetate and malonyl-CoA, wherein an enzyme which performs the carboxylation reaction is selected from the group consisting of phophoenolpyruvate (PEP) carboxlase, pyruvate carboxylase and acetyl-CoA carboxylase and wherein an export product of the carbon fixation pathway is glyoxylate. Additional carbon fixation pathways are also provided and methods of generating same.

Abstract translation: 提供了一种用于碳固定的系统。 该系统包括催化碳固定通道的反应的酶，其中碳固定通路的至少一个反应是羧化反应，其中碳固定路径的反应产物包含草酰乙酸和丙二酰辅酶A，其中酶 进行羧化反应的选自苯丙醇丙酮酸（PEP）羧基酶，丙酮酸羧化酶和乙酰​​辅酶A羧化酶，其中碳固定路径的出口产物是乙醛酸盐。 还提供了另外的碳固定路径和产生它们的方法。

公开(公告)号：US09387264B2

公开(公告)日：2016-07-12

申请号：US13856788

申请日：2013-04-04

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD ,  THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV

Inventor： Michal Neeman ,  Raz Zarivach ,  Marina Radoul ,  Batya Cohen ,  Moriel Vandsburger ,  Limor Lewin

IPC: A61K49/14 ,  C07K14/47 ,  C07K14/195

CPC classification number: A61K49/14 ,  C07K14/195 ,  C07K14/47 ,  C07K2319/00 ,  C07K2319/42

Abstract: The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging.

Abstract translation: 本发明提供融合铁蛋白，其中铁蛋白重链多肽与肽融合，其中该肽融合到铁蛋白重链的C末端; 并且肽在其N-末端包括至少一部分Mms6蛋白序列和至少一个异源氨基酸。 本发明还提供了用于磁共振成像的铁蛋白融合蛋白的使用方法。

公开(公告)号：US09382293B2

公开(公告)日：2016-07-05

申请号：US14384685

申请日：2013-03-14

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Matityahu Fridkin ,  Michal Cardon-Yaakov

IPC: C07K7/64 ,  C07K7/06 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K9/0053 ,  A61K38/00 ,  C07K7/64

Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.

Abstract translation: 本申请提供五至七个天然或非天然氨基酸的合成修饰肽以及包含它们的药物组合物，用于治疗与感觉门控功能障​​碍，抑郁症或认知障碍相关的行为异常的疾病或病症 ，特别是精神分裂症和阿尔茨海默病。

公开(公告)号：US09365828B2

公开(公告)日：2016-06-14

申请号：US14002782

申请日：2012-03-01

Applicant: Daniel Offen ,  Michal Dadon-Nachum ,  Tali Ben-Zur ,  Eldad Melamed ,  David Yaffe

Inventor： Daniel Offen ,  Michal Dadon-Nachum ,  Tali Ben-Zur ,  Eldad Melamed ,  David Yaffe

IPC: A01N63/00 ,  A61K48/00 ,  C12N5/077 ,  A61K35/34 ,  A61K35/12 ,  A61K38/00

CPC classification number: A61K35/34 ,  A61K35/12 ,  A61K38/00 ,  A61K38/185 ,  A61K38/1866 ,  A61K38/30 ,  C12N5/0658 ,  C12N5/0659 ,  C12N2501/105 ,  C12N2501/13 ,  C12N2501/165 ,  C12N2510/00

Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.

Abstract translation: 公开了分离的肌肉祖细胞是MyoD阳性，CD34阴性和CD45阴性。 肌肉祖细胞被遗传修饰以表达至少一种神经营养因子。 此外，公开了包含至少四个肌细胞亚群的细胞群，每个亚群被遗传修饰以表达不同的神经营养因子，其中所述神经营养因子选自神经胶质细胞衍生的神经营养因子（GDNF），胰岛素生长因子 IGF-1），血管内皮生长因子（VEGF）和脑源性神经营养因子（BDNF）。 还公开了细胞群体的用途。

公开(公告)号：US09309274B2

公开(公告)日：2016-04-12

申请号：US14488742

申请日：2014-09-17

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Milko E. Van Der Boom ,  Atindra D. Shukla ,  David Rosenblatt ,  Tarkeshwar Gupta

IPC: C07F15/00 ,  G02F1/15 ,  H01G9/22 ,  H01G9/20 ,  H01L51/00 ,  G01N27/30 ,  G01Q80/00 ,  G01N27/327 ,  C07F7/18

CPC classification number: C07F15/0026 ,  C07F7/1804 ,  C07F15/0053 ,  G01N27/30 ,  G01N27/305 ,  G01N27/3275 ,  G01Q80/00 ,  G02F1/15 ,  H01G9/2018 ,  H01G9/2059 ,  H01L51/0002 ,  H01L51/0086 ,  H01L51/0088 ,  Y02E10/542 ,  Y02E10/549 ,  Y10T29/49002

Abstract: A device is presented having reversibly changeable and optically readable optical properties. The device comprises a substrate having an electrically conductive surface and carrying a redox-active layer structure. The redox-active layer structure may be a monolayer or a multi-layer structure and is configured to have at least one predetermined electronic property including at least one of electrodensity and oxidation state. The electronic property of the layer structure defines an optical property of the structure thereby determining an optical response of the structure to certain incident light. This at least one electronic property is changeable by subjecting the redox-active layer structure to an electric field or to a redox-active material. The device thus enables effecting a change in said electronic property that results in a detectable change in the optical response of the layer structure.

Abstract translation: 呈现具有可逆变化和光学可读光学性质的装置。 该器件包括具有导电表面并承载氧化还原活性层结构的衬底。 氧化还原活性层结构可以是单层或多层结构，并且被配置为具有包括电密度和氧化态中的至少一种的至少一种预定的电子性质。 层结构的电子特性限定了该结构的光学特性，从而确定该结构对某些入射光的光响应。 通过使氧化还原活性层结构经受电场或氧化还原活性物质，该至少一种电子性质是可变化的。 因此，该装置能够实现导致层结构的光学响应的​​可检测变化的所述电子特性的变化。

公开(公告)号：US09289433B2

公开(公告)日：2016-03-22

申请号：US13872247

申请日：2013-04-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irina Lavelin ,  Varda Rotter ,  Moshe Oren ,  Ami Navon ,  Zvi Kam ,  Benjamin Geiger

IPC: A61K31/555 ,  A61K31/47 ,  A61K31/522 ,  A61K31/60 ,  A61K33/34 ,  C07K14/47 ,  C12N9/64 ,  G01N33/50 ,  A61K31/52

CPC classification number: A61K31/555 ,  A61K31/47 ,  A61K31/52 ,  A61K31/522 ,  A61K31/60 ,  A61K33/34 ,  C07K14/4746 ,  C07K2319/40 ,  C07K2319/60 ,  C12N9/6421 ,  C12Y304/25001 ,  G01N33/5035

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Abstract translation: 提供了治疗其中抑制蛋白酶体的优点的疾病的方法。 该方法包括向受试者施用治疗有效量的结合细胞蛋白酶体的化合物，所述化合物包含与配体结合的铜，所述配体被配置为使得在结合蛋白酶体时，铜与半胱氨酸相互作用 31的蛋白酶体的β2亚基，并进一步与蛋白酶体的β3亚基的半胱氨酸118相互作用，从而治疗该疾病。 还提供了另外的新型蛋白酶体抑制剂以及鉴定蛋白酶体抑制剂的方法。

公开(公告)号：US09286439B2

公开(公告)日：2016-03-15

申请号：US12808676

申请日：2008-12-17

Applicant: Ehud Y. Shapiro ,  Shai Kaplan ,  Gregory Linshiz ,  Tuval Ben-Yehezkel ,  Uri Shabi

Inventor： Ehud Y. Shapiro ,  Shai Kaplan ,  Gregory Linshiz ,  Tuval Ben-Yehezkel ,  Uri Shabi

IPC: G06F19/20 ,  G06F19/22 ,  G06F19/18

CPC classification number: G06F19/22 ,  G06F19/18

Abstract: A system and method for planning, manipulating, processing and editing DNA molecules utilizing a core operation on a given input DNA molecule to produce a targeted DNA molecule.

Abstract translation: 利用给定输入DNA分子的核心操作来规划，操纵，处理和编辑DNA分子以产生靶向DNA分子的系统和方法。